Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are evaluating the efficacy of dotinurad in lowering serum uric acid sUA levels in adults with gout who cannot tolerate xanthine oxidase inhibitors XOI or have failed uricase treatment. This Phase 2, randomized, double-blind, placebo-controlled study focuses on participants aged 18 to 75 with gout diagnosed for at least one year, assessing dotinurads ability to reduce sUA by Week 24. Participants are assigned to one of two groups one group receives dotinurad for 36 weeks, divided into a 24-week initial treatment period followed by a 12-week continuation. The other group takes placebo for the first 24 weeks and then switches to dotinurad for the final 12 weeks. Dotinurad is given orally as over-encapsulated tablets, while placebo capsules contain microcrystalline cellulose. This design allows comparison of dotinurad with placebo before all participants receive the active drug. During the study, participants undergo regular assessments including serum uric acid measurements at various timepoints up to Week 40. Researchers monitor the percentage of participants achieving target sUA levels, changes from baseline sUA, and treatment-emergent adverse events. Female participants of childbearing potential must have pregnancy tests and follow contraception requirements. The trial is expected to complete by August 2027, providing detailed safety and efficacy data over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the efficacy and safety of orforglipron in adults with overweight who are at risk of developing obesity-related complications such as type 2 diabetes, hypertension, and dyslipidemia, or progressing to class 1 obesity. The study is a phase 3, randomized, double-blind, placebo-controlled trial that aims to understand whether this oral medication can reduce these risks over a two-year period. Participants will be randomly assigned to one of three groups receiving orforglipron orally throughout, orforglipron followed by placebo, or placebo followed by orforglipron. The study involves daily oral administration of these medications. The trial includes a long-term treatment period lasting up to 104 weeks about two years, during which participants are monitored for weight changes and the onset of obesity-related health issues. Throughout the study, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood markers like glycated hemoglobin and triglycerides, and quality of life questionnaires. Researchers will also monitor the time to onset of obesity-related complications and pharmacokinetics of orforglipron at specified intervals. Safety and effectiveness will be tracked continuously, with the primary outcome being the time until the development of obesity-related complications or progression to class 1 obesity.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.
Actively Recruiting
Healthy Volunteer
Researchers are studying an investigational seasonal influenza vaccine based on messenger RNA mRNA in adults aged 18 to 64 years. This Phase 3 clinical trial aims to assess the immune response the vaccine triggers against influenza and to monitor any medical problems participants may experience after vaccination. The study also compares immune responses from adults 18 to 64 years old with those from adults 65 and older in a separate study. Participants will receive one injection into the upper arm muscle on Day 1. The trial includes multiple groups receiving either the investigational mRNA vaccine or one of two comparator vaccines. Those aged 60 to 64 years are included in a specific cohort receiving either the mRNA vaccine or comparator 2. The study uses a randomized, observer-blind, parallel design to compare these vaccines. During the study, participants will be followed for approximately six months. Researchers will collect blood samples before and after vaccination to measure antibody levels and immune responses. They will also monitor for adverse events, including local and systemic reactions, other medical events, serious events, and laboratory abnormalities. The main outcomes are antibody titers and seroconversion rates measured 29 days after vaccination, with safety assessed throughout the 6-month follow-up.
Actively Recruiting
Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of camlipixant in adults diagnosed with irritable bowel syndrome with diarrhea IBS-D and mixed irritable bowel syndrome IBS-M. This phase 2b study is designed to compare camlipixant with a placebo in relieving abdominal symptoms. The study includes two parts, with some participants randomly assigned in the second part to receive either a higher dose of the drug or to stop treatment. Participants will receive different doses of camlipixant or placebo during the first part of the study. In the second part, participants may receive either placebo or camlipixant again, allowing researchers to assess the effects of dose adjustments. The dosing levels include three different doses of camlipixant compared with placebo. The study treatment is given under double-blind conditions, meaning neither participants nor researchers know who receives which treatment. Throughout the study, participants will be monitored for changes in abdominal pain intensity and stool consistency over 12 weeks, with safety assessments continuing up to 26 weeks. Researchers will collect data on abdominal pain scores, stool form, global improvement, and any side effects or adverse events. Regular evaluations include physical exams, laboratory tests, and heart monitoring. Participants are expected to be involved in scheduled visits and assessments to track the study outcomes and ensure safety.
Actively Recruiting
Researchers are evaluating AXS-14 esreboxetine for managing fibromyalgia in a Phase 3, double-blind, placebo-controlled, randomized withdrawal study. The study aims to assess the efficacy and safety of AXS-14 for people diagnosed with fibromyalgia based on the 2016 ACR diagnostic criteria. The trial includes a multi-center design with two main periods. First, participants receive open-label AXS-14 tablets once daily for up to 12 weeks. Those who respond to treatment are then randomized to either continue AXS-14 or switch to placebo for an additional 12 weeks or until loss of therapeutic response occurs. Participants will be involved for up to 24 weeks in total. During this time, they will take study tablets daily and undergo assessments to monitor their response and safety. The primary outcome measured is the time from randomization to loss of therapeutic response over 12 weeks. Safety and efficacy are closely monitored throughout the study.
Actively Recruiting
Pain management during gynecologic procedures, especially saline infusion sonograms SIS used in fertility evaluations, is an important womens health issue as inadequate pain control may cause avoidance of necessary care. This trial evaluates whether local anesthesia using a lidocaine paracervical block reduces pain during SIS compared to a placebo procedure in women undergoing uterine and tubal assessments. The goal is to improve the patient experience and accessibility of SIS in fertility care. Participants are randomly assigned to receive either a paracervical block with 10cc of 1% lidocaine buffered with sodium bicarbonate or a placebo where a capped needle mimics injection without anesthesia. The study compares self-reported pain scores at multiple points during the procedure, including during the block administration, balloon catheter placement, saline infusion, and up to one hour after the procedure. This is a Phase 4, single-blind, parallel-group study. Women enrolled undergo saline infusion sonograms with balloon catheter assessments after taking ibuprofen beforehand. Researchers collect pain ratings during and after the procedure, record procedural details such as use of tenaculum or uterine sound, and monitor any inability to receive the block. The study measures changes in pain intensity during tubal patency assessment as the primary outcome and includes multiple secondary pain intensity measures. The trial runs from July 2025 to July 2027.
Actively Recruiting
Researchers are studying the prevention of recurrent Clostridioides difficile infection CDI in adults aged 18 and older. This Phase IIb clinical trial evaluates the safety and effectiveness of a drug called AZD5148 compared to a placebo. The trial is randomized, double-blind, and placebo-controlled, aiming to reduce the chance of CDI coming back. This study is sponsored by AstraZeneca and focuses on preventing infection recurrence in participants who have recently experienced CDI and are undergoing antibacterial treatment. Participants will be randomly assigned to receive a single dose of either AZD5148 or a placebo, given by either intramuscular injection or intravenous push as decided by the investigator. The treatment is administered once during the antibacterial therapy, which must last between 10 and 28 days. The study involves up to two visits for eligibility confirmation and dosing, followed by up to seven planned visits for monitoring. Participants will also complete an electronic diary and receive follow-up contacts weekly at first, then monthly. Participants will be closely monitored through stool sample collections, symptom tracking, and assessment of any adverse events. Researchers will evaluate the first recurrence of CDI within 91 days, duration and severity of diarrhea symptoms, hospitalizations related to CDI, and any adverse reactions to the study drug. Safety assessments continue for up to 361 days after dosing, including analysis of drug levels and immune responses. The total participation time may extend over a year to fully assess outcomes and safety.